![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLEKHA1 |
Gene summary for PLEKHA1 |
![]() |
Gene information | Species | Human | Gene symbol | PLEKHA1 | Gene ID | 59338 |
Gene name | pleckstrin homology domain containing A1 | |
Gene Alias | TAPP1 | |
Cytomap | 10q26.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9HB21 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
59338 | PLEKHA1 | LZE4T | Human | Esophagus | ESCC | 1.74e-18 | 6.88e-01 | 0.0811 |
59338 | PLEKHA1 | LZE5T | Human | Esophagus | ESCC | 1.65e-02 | 9.05e-02 | 0.0514 |
59338 | PLEKHA1 | LZE8T | Human | Esophagus | ESCC | 7.90e-03 | 9.36e-02 | 0.067 |
59338 | PLEKHA1 | LZE22T | Human | Esophagus | ESCC | 1.17e-06 | 4.24e-01 | 0.068 |
59338 | PLEKHA1 | LZE24T | Human | Esophagus | ESCC | 3.84e-18 | 5.99e-01 | 0.0596 |
59338 | PLEKHA1 | P1T-E | Human | Esophagus | ESCC | 2.09e-10 | 7.37e-01 | 0.0875 |
59338 | PLEKHA1 | P2T-E | Human | Esophagus | ESCC | 3.85e-29 | 6.53e-01 | 0.1177 |
59338 | PLEKHA1 | P4T-E | Human | Esophagus | ESCC | 1.27e-27 | 8.39e-01 | 0.1323 |
59338 | PLEKHA1 | P5T-E | Human | Esophagus | ESCC | 1.35e-31 | 7.00e-01 | 0.1327 |
59338 | PLEKHA1 | P8T-E | Human | Esophagus | ESCC | 6.00e-44 | 8.67e-01 | 0.0889 |
59338 | PLEKHA1 | P9T-E | Human | Esophagus | ESCC | 9.80e-17 | 4.75e-01 | 0.1131 |
59338 | PLEKHA1 | P10T-E | Human | Esophagus | ESCC | 6.67e-35 | 7.41e-01 | 0.116 |
59338 | PLEKHA1 | P11T-E | Human | Esophagus | ESCC | 5.41e-11 | 5.45e-01 | 0.1426 |
59338 | PLEKHA1 | P12T-E | Human | Esophagus | ESCC | 1.08e-49 | 1.25e+00 | 0.1122 |
59338 | PLEKHA1 | P15T-E | Human | Esophagus | ESCC | 7.54e-21 | 5.76e-01 | 0.1149 |
59338 | PLEKHA1 | P16T-E | Human | Esophagus | ESCC | 2.82e-23 | 3.15e-01 | 0.1153 |
59338 | PLEKHA1 | P17T-E | Human | Esophagus | ESCC | 1.35e-06 | 4.84e-01 | 0.1278 |
59338 | PLEKHA1 | P19T-E | Human | Esophagus | ESCC | 6.99e-06 | 7.17e-01 | 0.1662 |
59338 | PLEKHA1 | P20T-E | Human | Esophagus | ESCC | 1.52e-31 | 8.70e-01 | 0.1124 |
59338 | PLEKHA1 | P21T-E | Human | Esophagus | ESCC | 2.72e-31 | 5.19e-01 | 0.1617 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
GO:00069797 | Liver | NAFLD | response to oxidative stress | 78/1882 | 446/18723 | 7.85e-07 | 4.29e-05 | 78 |
GO:00485115 | Liver | NAFLD | rhythmic process | 56/1882 | 298/18723 | 3.03e-06 | 1.23e-04 | 56 |
GO:00352643 | Liver | NAFLD | multicellular organism growth | 27/1882 | 132/18723 | 2.57e-04 | 4.19e-03 | 27 |
GO:00621977 | Liver | NAFLD | cellular response to chemical stress | 54/1882 | 337/18723 | 3.83e-04 | 5.73e-03 | 54 |
GO:00425427 | Liver | NAFLD | response to hydrogen peroxide | 28/1882 | 146/18723 | 6.01e-04 | 7.97e-03 | 28 |
GO:00003027 | Liver | NAFLD | response to reactive oxygen species | 38/1882 | 222/18723 | 7.63e-04 | 9.63e-03 | 38 |
GO:00345997 | Liver | NAFLD | cellular response to oxidative stress | 46/1882 | 288/18723 | 1.07e-03 | 1.25e-02 | 46 |
GO:00424452 | Liver | NAFLD | hormone metabolic process | 36/1882 | 218/18723 | 1.98e-03 | 1.98e-02 | 36 |
GO:00480082 | Liver | NAFLD | platelet-derived growth factor receptor signaling pathway | 13/1882 | 56/18723 | 3.12e-03 | 2.79e-02 | 13 |
GO:0008210 | Liver | NAFLD | estrogen metabolic process | 10/1882 | 38/18723 | 3.49e-03 | 3.00e-02 | 10 |
GO:0060325 | Liver | NAFLD | face morphogenesis | 8/1882 | 28/18723 | 5.07e-03 | 3.96e-02 | 8 |
GO:000697912 | Liver | Cirrhotic | response to oxidative stress | 196/4634 | 446/18723 | 2.80e-19 | 5.86e-17 | 196 |
GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
GO:006219712 | Liver | Cirrhotic | cellular response to chemical stress | 147/4634 | 337/18723 | 1.84e-14 | 1.72e-12 | 147 |
GO:003459912 | Liver | Cirrhotic | cellular response to oxidative stress | 127/4634 | 288/18723 | 4.29e-13 | 3.32e-11 | 127 |
GO:000030212 | Liver | Cirrhotic | response to reactive oxygen species | 100/4634 | 222/18723 | 2.92e-11 | 1.73e-09 | 100 |
GO:004254212 | Liver | Cirrhotic | response to hydrogen peroxide | 71/4634 | 146/18723 | 3.40e-10 | 1.63e-08 | 71 |
GO:00346147 | Liver | Cirrhotic | cellular response to reactive oxygen species | 70/4634 | 155/18723 | 2.27e-08 | 7.91e-07 | 70 |
GO:00703012 | Liver | Cirrhotic | cellular response to hydrogen peroxide | 46/4634 | 98/18723 | 1.49e-06 | 2.93e-05 | 46 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLEKHA1 | SNV | Missense_Mutation | c.1162N>C | p.Asp388His | p.D388H | Q9HB21 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
PLEKHA1 | SNV | Missense_Mutation | c.358G>C | p.Asp120His | p.D120H | Q9HB21 | protein_coding | deleterious(0.01) | possibly_damaging(0.497) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PLEKHA1 | SNV | Missense_Mutation | c.635N>G | p.Tyr212Cys | p.Y212C | Q9HB21 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
PLEKHA1 | deletion | Frame_Shift_Del | novel | c.36delN | p.Leu14Ter | p.L14* | Q9HB21 | protein_coding | TCGA-E2-A15P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
PLEKHA1 | SNV | Missense_Mutation | rs374805648 | c.389N>A | p.Arg130His | p.R130H | Q9HB21 | protein_coding | tolerated(0.14) | benign(0.411) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
PLEKHA1 | SNV | Missense_Mutation | c.107N>G | p.Glu36Gly | p.E36G | Q9HB21 | protein_coding | tolerated(0.45) | benign(0.01) | TCGA-AA-3496-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLEKHA1 | SNV | Missense_Mutation | c.487N>C | p.Cys163Arg | p.C163R | Q9HB21 | protein_coding | tolerated(0.53) | benign(0.039) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
PLEKHA1 | SNV | Missense_Mutation | rs765456729 | c.934N>A | p.Ala312Thr | p.A312T | Q9HB21 | protein_coding | tolerated(0.39) | benign(0) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
PLEKHA1 | SNV | Missense_Mutation | rs771484933 | c.985C>T | p.Arg329Cys | p.R329C | Q9HB21 | protein_coding | tolerated(0.19) | benign(0) | TCGA-F4-6459-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PLEKHA1 | SNV | Missense_Mutation | rs769179533 | c.26N>A | p.Arg9His | p.R9H | Q9HB21 | protein_coding | deleterious(0.03) | possibly_damaging(0.802) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |